Keyphrases
Distant Metastasis
100%
Metastatic Melanoma
100%
Clinical Benefit
50%
Recent Advances
50%
Overall Survival
50%
Dendritic Cells
50%
Interferon-α (IFN-α)
50%
Immunomodulation
50%
Interleukin-2
50%
Detrimental Effects
50%
Randomized Trial
50%
Adoptive Immunotherapy
50%
FDA-approved Drugs
50%
Antigen Presentation
50%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
50%
Monoclonal Antibody
50%
Intratumor
50%
Biochemotherapy
50%
Antibody Targeting
50%
CD137
50%
Autologous Vaccine
50%
Interleukin-21 (IL-21)
50%
Antigen Processing
50%
Vaccine Delivery
50%
Vaccine Preparation
50%
Dendrimeric Peptide
50%
Gene Transfer Techniques
50%
Allogeneic Vaccine
50%
Melanoma Vaccine
50%
Vaccine Stabilization
50%
Medicine and Dentistry
Metastatic Carcinoma
100%
Immunotherapy
100%
Antigen Presentation
100%
Metastatic Melanoma
100%
Overall Survival
50%
Dendritic Cell
50%
Immunomodulation
50%
Monoclonal Antibody
50%
Arm
50%
Interferon
50%
CTLA-4
50%
CD137
50%
Interleukin 2
50%
Gene Transfer
50%
Interleukin 21
50%
Adoptive Immunotherapy
50%
Melanoma Vaccine
50%
Immunology and Microbiology
Immunotherapy
100%
Antigen Presentation
100%
Overall Survival
50%
Dendritic Cell
50%
interferon
50%
CTLA-4
50%
Arm
50%
Monoclonal Antibody
50%
Interleukin 2
50%
Adoptive Immunotherapy
50%
Immunomodulation
50%
Gene Transfer
50%
Melanoma Vaccine
50%
Interleukin 21
50%
Pharmacology, Toxicology and Pharmaceutical Science
Metastasis
100%
Immunotherapy
100%
Metastatic Melanoma
66%
Overall Survival
33%
Interferon
33%
Monoclonal Antibody
33%
Interleukin 2
33%
Interleukin 21
33%
Melanoma Vaccine
33%
Immunomodulation
33%
Gene Delivery
33%
Cytotoxic T Lymphocyte Antigen 4
33%